Literature DB >> 16721649

Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy.

J T Langfitt1, B G Vickrey, M P McDermott, S Messing, A T Berg, S S Spencer, M R Sperling, C W Bazil, S Shinnar.   

Abstract

Generic, preference-based instruments are recommended for assessing health-related quality of life (HRQOL) in cost-utility analyses (CUA). We aimed to determine which instrument is the most appropriate for CUA of epilepsy care, using established psychometric criteria. We compared validity and responsiveness of EQ5D (using both UK and US preferences), visual analog scale (VAS), Health Utilities Index Mark II (HUI-2) and Mark III (HUI-3) and SF6D in 165 adults evaluated for epilepsy surgery. SF6D had the strongest or next-strongest associations with seizure severity and seizure control. It was not associated with education or IQ. Only SF6D and HUI-3 discriminated between patients with and without seizures 2 years after baseline evaluation. SF6D was most or next-most responsive to being seizure-free for 2 years, in most responsiveness analyses. VAS was also responsive, but showed less evidence of validity. The QOLIE-89, an epilepsy-targeted profile instrument, had stronger evidence for validity and responsiveness than the preference instruments. SF6D has several key psychometric advantages over four other preference instruments in CUAs of epilepsy care. This may reflect better coverage of HRQOL dimensions affected by epilepsy, greater sensitivity at the upper end of the HRQOL continuum, or both. These findings may not generalize to other chronic conditions.

Entities:  

Mesh:

Year:  2006        PMID: 16721649     DOI: 10.1007/s11136-005-5231-3

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  68 in total

1.  The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain.

Authors:  William Hollingworth; Richard A Deyo; Sean D Sullivan; Scott S Emerson; Darryl T Gray; Jeffrey G Jarvik
Journal:  Health Econ       Date:  2002-01       Impact factor: 3.046

2.  The estimation of a preference-based measure of health from the SF-36.

Authors:  John Brazier; Jennifer Roberts; Mark Deverill
Journal:  J Health Econ       Date:  2002-03       Impact factor: 3.883

3.  US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

Authors:  James W Shaw; Jeffrey A Johnson; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

4.  Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation.

Authors:  R A Deyo; P Diehr; D L Patrick
Journal:  Control Clin Trials       Date:  1991-08

5.  Health status of people with epilepsy compared with a general reference population.

Authors:  K Stavem; J H Loge; S Kaasa
Journal:  Epilepsia       Date:  2000-01       Impact factor: 5.864

Review 6.  Psychometric considerations in evaluating health-related quality of life measures.

Authors:  R D Hays; R Anderson; D Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

7.  A health-related quality of life instrument for patients evaluated for epilepsy surgery.

Authors:  B G Vickrey; R D Hays; J Graber; R Rausch; J Engel; R H Brook
Journal:  Med Care       Date:  1992-04       Impact factor: 2.983

8.  The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab.

Authors:  Anthony S Russell; Barbara Conner-Spady; Alisa Mintz; Walter P Maksymowych
Journal:  J Rheumatol       Date:  2003-05       Impact factor: 4.666

9.  Living with epilepsy: long-term prognosis and psychosocial outcomes.

Authors:  D P Shackleton; D G A Kasteleijn-Nolst Trenité; A J M de Craen; J P Vandenbroucke; R G J Westendorp
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

10.  Clinical evaluation of the WOMAC 3.0 OA Index in numeric rating scale format using a computerized touch screen version.

Authors:  R Theiler; J Spielberger; H A Bischoff; N Bellamy; J Huber; S Kroesen
Journal:  Osteoarthritis Cartilage       Date:  2002-06       Impact factor: 6.576

View more
  9 in total

1.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  A longitudinal comparison of 5 preference-weighted health state classification systems in persons with intervertebral disk herniation.

Authors:  Christine M McDonough; Tor D Tosteson; Anna N A Tosteson; Alan M Jette; Margaret R Grove; James N Weinstein
Journal:  Med Decis Making       Date:  2010-11-22       Impact factor: 2.583

Review 3.  Can The EQ-5D Detect Meaningful Change? A Systematic Review.

Authors:  Nalin Payakachat; Mir M Ali; J Mick Tilford
Journal:  Pharmacoeconomics       Date:  2015-11       Impact factor: 4.981

4.  Disease-targeted versus generic measurement of health-related quality of life in epilepsy.

Authors:  Christine B Baca; Barbara G Vickrey; Stefanie Vassar; Anne T Berg
Journal:  Qual Life Res       Date:  2014-11-21       Impact factor: 4.147

5.  Patient and societal value functions for the testing morbidities index.

Authors:  J Shannon Swan; Chung Yin Kong; Janie M Lee; Omosalewa Itauma; Elkan F Halpern; Pablo A Lee; Sergey Vavinskiy; Olubunmi Williams; Emilie S Zoltick; Karen Donelan
Journal:  Med Decis Making       Date:  2013-05-20       Impact factor: 2.583

6.  Cognitive-behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT.

Authors:  Laura H Goldstein; Emily J Robinson; Izabela Pilecka; Iain Perdue; Iris Mosweu; Julie Read; Harriet Jordan; Matthew Wilkinson; Gregg Rawlings; Sarah J Feehan; Hannah Callaghan; Elana Day; James Purnell; Maria Baldellou Lopez; Alice Brockington; Christine Burness; Norman A Poole; Carole Eastwood; Michele Moore; John Dc Mellers; Jon Stone; Alan Carson; Nick Medford; Markus Reuber; Paul McCrone; Joanna Murray; Mark P Richardson; Sabine Landau; Trudie Chalder
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

7.  Weighing the value of memory loss in the surgical evaluation of left temporal lobe epilepsy: a decision analysis.

Authors:  Elliot H Akama-Garren; Matt T Bianchi; Catherine Leveroni; Andrew J Cole; Sydney S Cash; M Brandon Westover
Journal:  Epilepsia       Date:  2014-09-19       Impact factor: 5.864

8.  The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial.

Authors:  Philippe Ryvlin; Frank G Gilliam; Dang K Nguyen; Gabriella Colicchio; Alfonso Iudice; Paolo Tinuper; Nelia Zamponi; Umberto Aguglia; Louis Wagner; Lorella Minotti; Hermann Stefan; Paul Boon; Mark Sadler; Paolo Benna; Pradheep Raman; Emilio Perucca
Journal:  Epilepsia       Date:  2014-04-22       Impact factor: 5.864

9.  Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam.

Authors:  Clara Mukuria; Tracey Young; Anju Keetharuth; Simon Borghs; John Brazier
Journal:  Qual Life Res       Date:  2016-12-21       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.